Cargando…

Treatment of Olfactory Disorders After SARS – CoViD 2 Virus Infection

OBJECTIVE: The benefit of a nasal corticosteroid in the treatment of persistent post-infectious smell disorders is not as clear in previous studies as is assumed for olfactory training. This study would therefore like to describe the treatment strategies using the example of a persistent olfactory d...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, F., Azar, C., Goektas, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051008/
https://www.ncbi.nlm.nih.gov/pubmed/36976171
http://dx.doi.org/10.1177/01455613231168487
_version_ 1785014760349106176
author Schmidt, F.
Azar, C.
Goektas, O.
author_facet Schmidt, F.
Azar, C.
Goektas, O.
author_sort Schmidt, F.
collection PubMed
description OBJECTIVE: The benefit of a nasal corticosteroid in the treatment of persistent post-infectious smell disorders is not as clear in previous studies as is assumed for olfactory training. This study would therefore like to describe the treatment strategies using the example of a persistent olfactory dysfunction as a result of a proven infection with SARS-CoViD-2-virus. METHODS: Twenty patients (average age of 33.9 ± 11.9 years) with hyposmia were included in this study from December 2020 to July 2021. Every second patient received additionally a nasal corticosteroid. The two resulting randomized groups of equal size were screened with the TDI test, a 20-item taste powder test for the assessment of retronasal olfaction and otorhinolaryngological examination. The patients were asked to train twice daily using a standardized odor training kit and followed up after 2 months and 3 months, respectively. RESULTS: We documented a significant overall improvement in olfactory ability over the investigation period in both groups. While the TDI score steadily increased on average under the combination therapy, the rise under olfactory training alone was initially steeper. This short-term interaction effect over mean two months was not statistically significant. According to Cohen, however, a moderate effect (eta(2) = 0.055, Cohen`s d = 0.5) can still be assumed. This effect could be explained by a possibly higher compliance at the beginning of the sole olfactory training due to the lack of further drug treatment offers. When the training intensity decreases, the recovery of the sense of smell stagnates. Adjunctive therapy ultimately outweighs this short-term benefit. CONCLUSIONS: The results reinforce the recommendation of early and consistent olfactory training on patients with dysosmia due to COVID-19. For continuous improvement of the sense of smell, an accompanying topical treatment seems at least to be worth consideration. The results should be optimized with larger cohorts and using new objective olfactometric methods.
format Online
Article
Text
id pubmed-10051008
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-100510082023-03-29 Treatment of Olfactory Disorders After SARS – CoViD 2 Virus Infection Schmidt, F. Azar, C. Goektas, O. Ear Nose Throat J Clinical Study OBJECTIVE: The benefit of a nasal corticosteroid in the treatment of persistent post-infectious smell disorders is not as clear in previous studies as is assumed for olfactory training. This study would therefore like to describe the treatment strategies using the example of a persistent olfactory dysfunction as a result of a proven infection with SARS-CoViD-2-virus. METHODS: Twenty patients (average age of 33.9 ± 11.9 years) with hyposmia were included in this study from December 2020 to July 2021. Every second patient received additionally a nasal corticosteroid. The two resulting randomized groups of equal size were screened with the TDI test, a 20-item taste powder test for the assessment of retronasal olfaction and otorhinolaryngological examination. The patients were asked to train twice daily using a standardized odor training kit and followed up after 2 months and 3 months, respectively. RESULTS: We documented a significant overall improvement in olfactory ability over the investigation period in both groups. While the TDI score steadily increased on average under the combination therapy, the rise under olfactory training alone was initially steeper. This short-term interaction effect over mean two months was not statistically significant. According to Cohen, however, a moderate effect (eta(2) = 0.055, Cohen`s d = 0.5) can still be assumed. This effect could be explained by a possibly higher compliance at the beginning of the sole olfactory training due to the lack of further drug treatment offers. When the training intensity decreases, the recovery of the sense of smell stagnates. Adjunctive therapy ultimately outweighs this short-term benefit. CONCLUSIONS: The results reinforce the recommendation of early and consistent olfactory training on patients with dysosmia due to COVID-19. For continuous improvement of the sense of smell, an accompanying topical treatment seems at least to be worth consideration. The results should be optimized with larger cohorts and using new objective olfactometric methods. SAGE Publications 2023-03-28 /pmc/articles/PMC10051008/ /pubmed/36976171 http://dx.doi.org/10.1177/01455613231168487 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Clinical Study
Schmidt, F.
Azar, C.
Goektas, O.
Treatment of Olfactory Disorders After SARS – CoViD 2 Virus Infection
title Treatment of Olfactory Disorders After SARS – CoViD 2 Virus Infection
title_full Treatment of Olfactory Disorders After SARS – CoViD 2 Virus Infection
title_fullStr Treatment of Olfactory Disorders After SARS – CoViD 2 Virus Infection
title_full_unstemmed Treatment of Olfactory Disorders After SARS – CoViD 2 Virus Infection
title_short Treatment of Olfactory Disorders After SARS – CoViD 2 Virus Infection
title_sort treatment of olfactory disorders after sars – covid 2 virus infection
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051008/
https://www.ncbi.nlm.nih.gov/pubmed/36976171
http://dx.doi.org/10.1177/01455613231168487
work_keys_str_mv AT schmidtf treatmentofolfactorydisordersaftersarscovid2virusinfection
AT azarc treatmentofolfactorydisordersaftersarscovid2virusinfection
AT goektaso treatmentofolfactorydisordersaftersarscovid2virusinfection